Serum NGAL as a Predictor of Clinical and Endoscopic Activity of Inflammatory Bowel Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05151458

Enrollment

Registered

2021-12-09

Start date

2021-12-29

Completion date

2022-11-30

Last updated

2021-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases

Brief summary

Ulcerative colitis (UC) and Crohns disease (CD) represent the two major forms of inflammatory bowel disease (IBD), characterized by epithelial cell damage and prominent mucosal infiltration by inflammatory cells including granulocytes, macrophages, lymphocytes, and plasma cells.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

IBD patients diagnosed by endoscopy. Male and female gender. Disease activity proven clinically and endoscopy . Assiut university hospital patients

Exclusion criteria

* Patients who refuse to contribute in this study Pregnancy and breast feeding Cancer patients Renal pathology Diabetes Mellitus Cardiovascular patients Pancreatitis COPD patients

Design outcomes

Primary

Measure	Time frame	Description
test the sensitivity and specificity of using NGAL in diagnosis of IBD	One year	test the sensitivity and specificity of using NGAL in diagnosis of IBD

Contacts

Primary ContactMohamed Alsadek Ma Ghozaly, Master

alsadekmohamed215@gmail.com01150993206

Backup ContactHossam Ma Abd Alwahab

01146539976

Outcome results